Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
Portfolio Pulse from Vandana Singh
Ipsen SA and Genfit SA announced positive topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis (PBC). The trial met its primary composite endpoint, with 51% of patients on elafibranor 80mg exhibiting a cholestasis response compared to 4% on placebo. Ipsen plans to discuss these results with regulatory bodies and aims to move forward with regulatory submissions to the FDA and the European Medicines Agency. Genfit shares are down 14.30% at $3.47 on the last check Friday.
June 30, 2023 | 6:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ipsen plans to discuss the positive trial results with regulatory bodies and aims to move forward with regulatory submissions.
The positive trial results are a good sign for Ipsen, and the company's plans to discuss these results with regulatory bodies could potentially lead to regulatory approval for elafibranor, which would be a positive development for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Genfit's shares are down 14.30% despite positive trial results for elafibranor.
Despite the positive trial results, the market reacted negatively to the news, causing Genfit's shares to drop. This could be due to a variety of factors, including market volatility or investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100